| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies; University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy
1 Division of Neurosurgery, Hospital of Padova, 35100 Padova, Italy
2 Biomeasure Incorporated/IPSEN, Milford, MA 01757-3650, USA
(Requests for offprints should be addressed to E C degli Uberti; Email: ti8{at}unife.it)
Dopamine (DA) and somatostatin (SRIF) receptor agonists inhibit growth hormone (GH) secretion by pituitary adenomas. We investigated DA subtype 2 receptor (DR2) and SRIF receptor (sst) subtypes 2 and 5 expression in 25 GH-secreting pituitary adenomas and tested in primary culture the effects on GH and prolactin (PRL) secretion of sst agonists selectively interacting with sst2 (BIM-23120), sst5 (BIM-23206), and sst2 and sst5 (BIM-23244). All adenomas expressed sst2; eight adenomas expressed both sst5 and DR2, eight sst5 but not DR2, and eight DR2 but not sst5. One tissue lacked expression of DR2 and sst5. GH secretion was inhibited by BIM-23120 in all samples, while it was reduced by BIM-23206 only in adenomas not expressing DR2. BIM-23120’s inhibitory effects correlated with sst2 and DR2 expression, whereas DR2 expression correlated inversely with BIM-23206 inhibitory effects on GH secretion. In seven mixed GH-/PRL-secreting pituitary adenomas, PRL secretion was inhibited in sst5-expressing tumors by BIM-23206, but not by BIM-23120. BIM-23244 reduced PRL secretion only in adenomas expressing sst2, sst5 and DR2. sst5 and DR2 expression correlated directly with BIM23206
This article has been cited by other articles:
|
|
 |
|
  L. V. Neto, E. d. O. Machado, R. M. Luque, G. F. Taboada, J. B. Marcondes, L. M. C. Chimelli, L. P. Quintella, P. Niemeyer Jr., D. P. de Carvalho, R. D. Kineman, et al. Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1931 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ferone, F. Gatto, M. Arvigo, E. Resmini, M. Boschetti, C. Teti, D. Esposito, and F. Minuto The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology J. Mol. Endocrinol., May 1, 2009; 42(5): 361 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gruszka, S.-G. Ren, J. Dong, M. D. Culler, and S. Melmed Regulation of Growth Hormone and Prolactin Gene Expression and Secretion by Chimeric Somatostatin-Dopamine Molecules Endocrinology, December 1, 2007; 148(12): 6107 - 6114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Resmini, P. Dadati, J.-L. Ravetti, G. Zona, R. Spaziante, A. Saveanu, P. Jaquet, M. D. Culler, F. Bianchi, A. Rebora, et al. Rapid Pituitary Tumor Shrinkage with Dissociation between Antiproliferative and Antisecretory Effects of a Long-Acting Octreotide in an Acromegalic Patient J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1592 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ferone, A. Saveanu, M. D Culler, M. Arvigo, A. Rebora, F. Gatto, F. Minuto, and P. Jaquet Novel chimeric somatostatin analogs: facts and perspectives Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S23 - S28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Zatelli, D. Piccin, F. Tagliati, A. Bottoni, A. Luchin, C. Vignali, A. Margutti, M. Bondanelli, G. C. Pansini, M. R. Pelizzo, et al. Selective Activation of Somatostatin Receptor Subtypes Differentially Modulates Secretion and Viability in Human Medullary Thyroid Carcinoma Primary Cultures: Potential Clinical Perspectives J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2218 - 2224. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
